The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 5, 2006, Pages 443-467

  Pellegrini, Patrizia ^a   Berghella, Anna Maria ^a   Contasta, Ida ^a   Del Beato, Tiziana ^a   Adorno, Domenico ^a  

^a CNR   (Italy)

Author keywords

Cancer biotherapy; Colon cancer; Immunological parameters; Prognostic indices; Stage classification; TH1 TH2 cytokines

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CLASSIFICATION; CANCER SCREENING; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; SCREENING TEST; TH1 CELL; TH2 CELL;

ANTIGENS, CD3; ANTIGENS, CD30; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKINS; MATRIX METALLOPROTEINASE 1; NEOPLASM STAGING; PROGNOSIS; TH1 CELLS; TH2 CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750966495     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.443     Document Type: Article

References (122)

1. Skeel RT. Handbook of Cancer Chemotherapy. Boston: Little Brown, 1992.
2. Teicher BA. In: Armitage JO, Antman KH eds. High-Dose Cancer Therapy. Baltimore: Williams & Wilkins, 1992:14.
3. Yahalom I, Fuks YZ. In: Armitage JO, Antman KH, eds. High-Dose Cancer Therapy. Baltimore: Williams & Wilkins, 1992:61.
4. Van Geelen CMM, De Vries EGE, De Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy. Drug Resist Updates 2004;7(6):345.
5. Cohen AM, Shank B, Friedman M. In: De Vita VT, Hellman SY, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 1989:895.
6. Danenberg PV, Danenberg KD. Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism. Biochemistry 1978;17:4018.
7. Lokich JL, Alhgren JD, Gullo JJ. A prospective, randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. Oncology Program Study. J Clin Oncol 1989;7:425.
8. Shah A, MacDonald W, Goldie J. 5-FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 1985;69:739.
9. Aramda E, Diaz-Rubio E, Camps C. In: Banset P, Holland JF, Khayat D, Weil M eds. Cancer Treatment: an Update. New York: Springer-Verlag, 1994.
10. Haydon A. Adjuvant chemotherapy in colon cancer: What is the evidence? Intern Med J 2003;33(3): 119.
11. International Multicentre Pooled Analysis of B 2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999;17(5):1356.
12. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17(5):1349.
13. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995;122(5):321.
14. Jiang Q, Chen K, Ma X, et al. Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. Cancer Detect Prevent 2005;29(2):146.
15. Lipkin M. Biomarkers of increased susceptibility to gastrointestinal cancer: New application to studies of cancer prevention in human subjects. Cancer Res 1988;48:235.
16. Pence BC. Role of calcium in colon cancer prevention: Experimental and clinical studies. Mut Res 1993;290(1):87.
17. Meterissian SH, Forse RA, Steele GD, et al. Effect of membrane-free fatty acid alterations on the adhesion of human colorectal carcinoma cells to liver macrophages and extracellular matrix proteins. Cancer Lett 1995;89(2):145.
18. Jamal HH, Cano-Gauci DF, Buick RN, et al. Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 1994;9(2):417.
19. Ponz de Leon M, Sant M, Micheli A, et al. Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study. Cancer 1992;69:626.
20. Garagliano CF. In: Rotter JI, Samloff IM, Rimoln DL, eds. Genetics and Heterogeneity of Common Gastrointestinal Disorders New York: Academic Press, 1980:323.
21. Burt RW, Bishop DT, Cannon LA, et al. Dominant inheritance of adenomatous colonic polyps and colorectal cancer. N Engl J Med 1985;312:1540.
22. Cannon-Albright LA, Skolnick MH, Bishop DT, et al. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 1988;319:533.
23. Yaremko ML, Wasylyshyn ML, Westbrook C, et al. Oncogenes, suppressor genes, and allele losses in colon cancer. Adv Surg 1993;26:323.
24. Vogelstein B, Fearon E, Hamilton S, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525.
25. Huang F, Hsu SD, Yan Z, et al. The capacity for growth stimulation by TGF beta-1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53, or ras. Oncogene 1994;9(12):3701.
26. Redston MS, Papadopoulos M, Caldas C, et al. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 1995;108(2):383.
27. Minamoto T, Yamashita N, Ochiai A, et al. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer 1995;75(Suppl 6):1520.
28. Pretlow TP, Brasitus TA, Fulton NC, et al. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 1993;85(24):2004.
29. American Joint Committee on Cancer. 1992 Manual for staging of cancer In: Beahrs OH, Henson DE, Hutter RVP, et al, eds. Philadelphia: Lippincott, 1992:3.
30. Berghella AM, Pellegrini P, Piancatelli D, et al. Progression mechanisms in colon cancer: Soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response, and tumour stage correlations. Cancer Immunol Immunother 1994;38:160.
31. + T-cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996;42:1.
32. Pellegrini P, Berghella AM, Del Beato T, et al. Immunological directives for biotherapy improvement in the treatment of colorectal cancer. Cancer Biother Radiopharm 1996;11:113.
33. Contasta I, Pellegrini P, Berghella AM, et al. Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm 1996;11:373.
34. Del Beato T, Berghella AM, Pellegrini P, The role of the soluble CD30 serum level in colorectal cancer: A possible marker for a patient subset which could benefit from IL-2 biotherapy. Cancer Biother Radiopharm 1997;12(5):297.
35. Contasta I, Pellegrini P, Berghella AM, et al. Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: Indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding. Cancer Biother Radiopharm 1997;12(6):385.
36. Pellegrini P, Berghella AM, Del Beato T, et al. The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm 1997;12:257.
37. Berghella AM, Pellegrini, P, Del Beato, T, et al. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 1998;45:241.
38. Contasta I, Berghella AM, Pellegrini P, et al. Relationships between the activity of MMP1/TIMP1 enzymes and the TH1/TH2 cytokine network. Cancer Biother Radiopharm 1999;14(6):465.
39. Pellegrini P, Contasta I, Berghella AM, et al. The TH1 and TH2 cytokine network in healthy subjects: Suggestions for experimental studies to create prognostic and diagnostic indices for biotherapeutic treatments. Cancer Biother Radiopharm 2000;15(3):267.
40. Jenkins MP, Alvaranga JC, Thomas JM. The management of retroperitoneal soft-tissue sarcomas. Eur J Cancer 1996;32A(4):622.
41. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metast Rev 2005;24(1):95.
42. Berghella AM, Pellegrini P, Del Beato T, et al. Prognostic significance of immunological evaluation in colorectal cancer. Cancer Biother Radiopharm 1996; 11:355.
43. Berghella AM, Pellegrini P, Del Beato-T, et al. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer. Cancer Biother Radiopharm 1997; 12(4):265.
44. Pellegrini P, Berghella AM, Del Beato T, et al. Disease stage prognostic indices in the early clinical screening of colorectal cancer patients. Cancer Biother Radiopharm 1998;13:89.
45. Pellegrini P, Contasta I, Berghella AM, et al. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of preinvasive to invasive colorectal cancer. Cancer Immunol Immunother 2000;49(7):388.
46. Contasta I, Pellegrini P, Berghella AM, et al. Cell-cycle control in cellular homeostasis during the immune response: Interactions between TH1, TH2 cytokines, and Bcl2 and p53 molecules. Cancer Biother Radiopharm 2001;16(1):63.
47. Berghella AM, Contasta I, Pellegrini P, et al. Peripheral blood immunological parameters for use as markers of preinvasive to invasive colorectal cancer. Cancer Biother Radiopharm 2002;17:43.
48. Contasta I, Berghella AM, Pellegrini P, et al. Passage from normal mucosa to adenoma and colon cancer: Alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 2003;18(4):549.
49. Pellegrini P, Berghella AM, Contasta I, et al. CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003;12(1):49.
50. Pellegrini P, Totaro R, Contasta, I, et al. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis. Neuroimmunomodulation 2005;12(4):220.
51. Berghella AM, Pellegrini P, Contasta I, et al., eds. New Immunology Research. Hauppauge, NY: Nova Science Publishers, 2005.
52. Cher DJ, and Mosmann TR. Two types of murine helper T-cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987;138:3688.
53. Stevens TL, Bossie A, Sanders WM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T-cells. Nature 1988;334:255.
54. Chatelain R, Varkila K, Coffman RL. IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol 1992;148:1182.
55. Kopf M, Le Gros G, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245.
56. + T-cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589.
57. Schwarz EM, Salgame P, Bloom BR. Molecular regulation of human interleukin-2 and T-cell function by interleukin-4. Proc Natl Acad Sci USA 1993;90: 7734.
58. Smith C, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;248:1019.
59. Namen AE, Schmierer AE, March CJ, et al. B-cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988;167:988.
60. Namen AE, Lupton S, Hjerrild J, et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988;333:571.
61. Morrissey PJ, Goodwin RG, Nordan RP, et al. Recombinant interleukin-7, pre-B cell-growth factor, has costimulatory activity on purified mature T-cells. J Exp Med 1989;169:707.
62. Grabstein KH, Namen AE, Shanerbeck K, et al. Regulation of T-cell proliferation by IL-7. J Immunol 1990;144:3015.
63. Lynch DH, Miller RE. Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol 1990;145:1983.
64. Hickman CJ, Crim JA, Mostowski HS, et al. Regulation of human cytotoxic T-lymphocyte development by IL-7. J Immunol 1990;145:2415.
65. Alderson MR, Tough TW, Ziegler SF, et al. Interleukin-7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991;173:923.
66. Leonard EJ, Skeel A, Yoshimura T, et al. Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. J Immunol 1990;144: 1323.
67. Larsen CG, Anderson AO, Appella E, et al. The neutrophil-activating protein (NAP-1) is also chemotactic for T-lymphocytes. Science 1989;243:1464.
68. Solomkin JS, Bass RC, Bjomson HS, et al. Alterations of neutrophil responses to tumor necrosis factor alpha and interleukin-8 following human endotoxemia. Infect Immun 1994;62:943.
69. Webb DSA, Mostowski HS, Gerrard TL. Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol 1991;146:3682.
70. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425.
71. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989;34:619.
72. Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol 1991;147:3788.
73. Albert-Wolf M, Meuer SC, and Wallich R. Dual function of recombinant human CD58: Inhibition of T-cell adhesion and activation via the CD2 pathway. Int Immunol 1991;3:1335.
74. Randerson PF. In: Fry JC, ed. Biological Data Analysis. A Practical Approach. Oxford/New York: IRL Press, Oxford University Press, 1993:173.
75. Statgraphics-full system 5.25, Version 4.0. Statistical Graphics System By Statistical Graphics Corporation. Beaverton, OR, 1989.
76. Fry JC. A Practical Approach. In: Fry JC, ed. New York: Oxford University Press, 1993.
77. Bando E, Yonemura Y, Endou Y, et al. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol Rep 1998;5(6):1483.
78. Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998;79:96.
79. Nutt JE, Mellon J, Qureshi K, et al. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br J Cancer 1998;78(2):215.
80. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis, and angiogenesis. Eur Respir J 1994;7(11):2062.
81. Cao J, Rehemtulla A, Bahou W, et al. Membrane-type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 1996;271(47):30174.
82. Murphy G, Cockett MI, Stephens PE, et al. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 1987;248(1):265.
83. Cawston TE, Galloway WA, Mercer E, et al. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981;195(1):159.
84. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264(29):17374.
85. Murphy G, Koklitis P, Carne AF. Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. Biochem J 1989;261(3):1031.
86. Bielicki D, Karbowniczek M, Sulzyc-Bielicka V, et al. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies. Pol J Pathol 1999;50(2):77.
87. Prado BI, Laudanna AA, Carneiro CRW. Susceptibility of colorectal-carcinoma cells to natural-killer-mediated lysis: Relationship to CEA expression and degree of differentiation. Int J Cancer 1995;61:854.
88. Nakamura T, Tabuchi Y, Nakae S, et al. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival. Cancer 1996;77(8 Suppl S):1741.
89. Houbiers JG, van der Burg SH, van de Watering LM, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995; 72(3):637.
90. Peyrat JP, Bonneterre J, Lubin R, et al. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345(8950):621.
91. McCarthy K, Maguire T, McGreal G, et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84(1):44.
92. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, et al. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999;86(8):1421.
93. Kanavaros P, Stefanaki K, Valassiadou K, et al. Expression of p53, p21/waf, bcl-2, bax, Rb, and Ki67 proteins in colorectal adenocarcinomas. Med Oncol 1999;16(1):23.
94. Maehara Y, Tomoda M, Hasuda S, et al. Prognostic value of p53 protein expression for patients with gastric cancer-a multivariate analysis. Br J Cancer 1999;79(7-8):1255.
95. Sada M, Mitomi H, Igarashi M, et al. Cell kinetics, p53, and bcl-2 expression, and c-Ki-ras mutations in flat-elevated tubulovillous adenomas and adenocarcinomas of the colorectum: Comparison with polypoid lesions. Scand J Gastroenterol 1999;34(8):798.
96. Bloom BR, Salgame P, Diamond B. Revisiting and revising suppressor T-cells. Immunol Today 1992;13:131.
97. + T-cells. Immunol Rev 1991;123:209.
98. + T-cell subsets in vivo. Immunol Rev 1991;123:189.
99. + T-cell subsets producing a selective pattern of lymphokines in the pathogenesis of human chronic inflammatory and allergic diseases. Immunol Rev 1991;123:23.
100. Murray JS, Madri J, Pasqualini T, et al. Functional CD4 T-cell subset interplay in an intact immune system. J Immunol 1993;150:4270.
101. Thomson AW, Dinarello, CA, Goldsmith, MA, et al. In: Thomson A, ed. The Cytokine Handbook. San Diego, CA: Academic Press, 1994.
102. Tanaka T, Hu-Li J, Seder RA, et al. Interleukin-4 suppresses interleukin-2 and interferon gamma production by naïve T-cells stimulated by accessory cell-dependent receptor engagement. Proc Natl Acad Sci USA 1993;90:5914.
103. Chen L, Tourvielle B, Burns GF, et al. Interferon: A cytotoxic T-lymphocyte differentiation signal. Eur J Immunol 1986;16:767.
104. Gillis S, Gillis AE, Henney CS. Monoclonal antibody directed against interleukin-2. I. Inhibition of T-lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T-cells. J Exp Med 1981;154:983.
105. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T-cells. J Immunol 1989;143:1210.
106. Wagner H, Hardt C, Rouse BT, et al. Dissection of the proliferative and differentiative signals controlling murine cytotoxic T-lymphocyte responses. J Exp Med 1982;155:1876.
107. + cytotoxic T-lymphocytes. J Immunol 1989;143:1518.
108. Daly LM, Johnson PA, Donnelly G, et al. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine 2005; 23(7):963.
109. Mule JJ, Custer MC, Travis WD, et al. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992;148:2622.
110. Bradley LM, Yoshimoto K, Swain SL. The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T-cells in vitro. J Immunol 1995;155:1713.
111. Banchereau J. Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Inst Mitteilungen 1995;96:58.
112. Fossa SD, Aamdal S, Naume B, et al. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal-cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy. Acta Oncol 1995;34:599.
113. Lopez M, Di Lauro L, Paoletti G, et al. Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin, and interleukin-2: Clinical and immunological effects. Ann Oncol 1995;6:1011.
114. Wasik MA, Vonderheid EC, Bigler RD, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996;132:42.
115. Doyle A, Stein M, Keshav S, et al. In: Balkwill FR, ed. Cytokines: A Practical Approach. New York: Oxford University Press, 1993.
116. + human T-lymphocyte subsets. Eur J Immunol 1993;23:61.
117. Welge T, Wolf M, Jaggle C, et al. Human naive T- cells are preferentially stimulated by cross-linking of CD3 and CD45RA with monoclonal antibodies. Cell Immunol 1993;148:218.
118. Williams ME, Lichtman AH, Abbas AK. Anti-CD3 antibody induces unresponsiveness to IL-2 in Th1 clones but not in Th2 clones. J Immunol 1990;144:1208.
119. Stanley CJ, Ragini F. In: Remick DG, Friedland JS, eds., Cytokines in Health and Disease. New York: Marcel Dekker, 1997.
120. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994;76:959.
121. Durkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421.
122. Chiarle R, Podda A, Prolla G, et al. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999;163:194.